Human ADME for YH12852 using wavelength scanning cavity ring-down spectroscopy (WS-CRDS) after a low radioactivity dose.Aim: Human 14C radiotracer studies provide information-rich data sets that enable informed decision making in clinical drug development. 
WS-CRDS
Human ADME for YH12852 using wavelength scanning cavity ring-down spectroscopy (WS-CRDS) after a low radioactivity dose.Aim: Human 14C radiotracer studies provide information-rich data sets that enable informed decision making in clinical drug development.  Mid-infrared laser-based 'cavity ring-down spectroscopy' (CRDS) is an emerging platform for the sensitive quantitation of 14C tracers.  Results & methodology: We compared the total 14C concentrations in plasma and urine samples from a microtracer study using both CRDS and AMS technology.  Conclusion: The CRDS method closely reproduced the AMS method for total 14C concentrations. 
CRDS
These studies are supported by liquid scintillation counting after conventional-sized 14C doses (50-200 μCi) or complex accelerator mass spectrometry (AMS) after microtracer-sized doses (∼0.1-1 μCi).  Results & methodology: We compared the total 14C concentrations in plasma and urine samples from a microtracer study using both CRDS and AMS technology.  Conclusion: The CRDS method closely reproduced the AMS method for total 14C concentrations. 
AMS
Human ADME for YH12852 using wavelength scanning cavity ring-down spectroscopy (WS-CRDS) after a low radioactivity dose.Aim: Human 14C radiotracer studies provide information-rich data sets that enable informed decision making in clinical drug development.  Mid-infrared laser-based 'cavity ring-down spectroscopy' (CRDS) is an emerging platform for the sensitive quantitation of 14C tracers.  Results & methodology: We compared the total 14C concentrations in plasma and urine samples from a microtracer study using both CRDS and AMS technology.  Conclusion: The CRDS method closely reproduced the AMS method for total 14C concentrations. 
CRDS
These studies are supported by liquid scintillation counting after conventional-sized 14C doses (50-200 μCi) or complex accelerator mass spectrometry (AMS) after microtracer-sized doses (∼0.1-1 μCi).  Results & methodology: We compared the total 14C concentrations in plasma and urine samples from a microtracer study using both CRDS and AMS technology.  Conclusion: The CRDS method closely reproduced the AMS method for total 14C concentrations. 
AMS